[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -1.57% 47.00 47.00 48.50 47.75 47.75 47.75 60,604 16:35:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.1 3.3 2.7 17.2 59

Venture Life Share Discussion Threads

Showing 35951 to 35975 of 36025 messages
Chat Pages: 1441  1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  Older
DateSubjectAuthorDiscuss
16/8/2021
22:19
I agree with Simon Thomson from the Investors Chronicle that the share price fall has been a massive over-reaction; hence why I did not sell a single share. His summary below: So, with Ebitda forecast to rise by £3.5m and depreciation charges and amortisation charges only rising by £0.5m, then effectively 85 per cent of next year’s Ebitda growth should be converted into operating profit, hence why Cenkos expect operating profit to rise from £5.6m to £8.5m in 2022 and deliver 38 per cent higher EPS of 6.21p. On this basis, the shares are trading on a miserly, forward PE ratio of 10.5. If anything, the risk to 2022 earnings estimates is skewed to the upside. That’s because Randall confirmed that the company has firepower of £20m plus through Venture’s new bank facility to make further earnings accretive acquisitions. In my view, there has been a massive overreaction to last week’s trading update – 2022 forecasts are in line with the expectations I outlined in last week’s article – and the share price fall is not only overdone, but is likely to prove a cracking buying opportunity. I am certainly not changing my 130p target price. Buy.
melody9999
16/8/2021
20:35
Just learned Jerry Randall was ex Sinclair Pharma. Bit of digging on advfn suggests he didn't look after shareholders at SPH either. The man has form.
farnesbarnes
16/8/2021
17:13
ST not flinched. Retains 130p price target from last week and outlines rationale in IC article released tonight.
toptomcat
14/8/2021
15:21
Yep, wonder as well if ST's article was a nice pump to exit!.
disc0dave45
14/8/2021
15:01
Be interesting to see where this settles. Will it bounce or drift lower, suspect the latter. If you can't trust the management it's only more difficult and a decent rating is probably unlikely. Hate it when management sell knowing horrendous news is almost certainly just around the corner.
its the oxman
13/8/2021
16:10
Absolutely redwing1, I meant the recently acquired Kelo-cote production rights.
rivaldo
13/8/2021
15:34
Rivaldo - I'm pretty sure they don't own Kelocote. They just manufacture for Alliance Pharma. Red flags everywhere with VLG. Directors selling whilst raising funds to make deals says it all. Chinese mega order but virtually no actual sales is dodgy too. Fetch me the barge pole!!!
redwing1
13/8/2021
15:28
Sold my entire holding. Completely untrustworthy. I can’t think of a worse RNS in the past few years (for my holdings).
jockthescot75
13/8/2021
13:47
Wouldn't believe a word this BOD says. So China sales down 91% in H1 yet in their finals in March, all they said as an update was deliveries had commenced, jeez Q1 deliveries would have been virtually zero yet they preferred to gloss over it.In April last year they said they'd received an order from China for €7m (about £6m), but at year end sales were only about £1.6m, again all they could say was they'd seen some "challenges".IMO Can't see 3p eps this FY and on a PE of 23 with potentially more pw's to come then stay clear.Bunch of cowboys IMO, no wonder they offloaded a stack at 90p.
disc0dave45
13/8/2021
11:49
Riv, that all may be the case but the lack of delivery mate on China is awful, likewise they've done 2 deals and raised an RCF then delivered IMO a profit warning which will not endear them to anyone. Management need a time of delivery to consensus IMO before they will get a decent rating again.....maybe I'm wrong but all a little smelly and selling pressure may see it lower and will take newsflow and positive newsflow IMO to get this motoring.... DYOR
qs99
13/8/2021
11:30
...this management have increased the share price by almost 150% to the current 73.5p in the last 18 months or so. Not so bad. Cenkos have now raised their forecasts to 4.53p adjusted EPS this year, rising to 6.21p EPS next year. That's a P/E of 16.2 falling to just 11.8, now incorporating the acquisitions. It's still possible that there'll be another earnings-enhancing acquisition or two soon. Management have earned the market's distrust with (a) share sales and (b) failing to flag the extent of the drop in the "one-off" sales of hand sanitiser and Dentyl China. Nevertheless, this doesn't mean that the core business is not a good, steadily growing business with lots of growth potential from both existing production facilities and the current product portfolio. Just look at the success of the relatively recently acquired Kelo-cote, which presumably is part of the reason why the order book excluding the "one-offs" is up 9%. IMO this company may, looking forward, be considered to have been an absolute bargain at these levels. EDIT - thanks for that Simon. Interesting to see the difference between the Cenkos and Singer numbers. Singer show absolutely no workings or detail, whereas Cenkos' note is far more detailed. I note that Singer now have a 130p fair valuation "using a peer-based 15x EV/EBITDA multiple".
rivaldo
13/8/2021
11:29
Singer - 13/8/21: 2021 T/O - 35.5m PBT - 5.5m EPS - 3.1p Net Cash - zero 2022 T/O - 45m PBT - 6.7m EPS - 3.8p Net Cash - 5.9m What's a fair forward multiple 13x?
simon gordon
13/8/2021
10:09
What a shambles this Company is ! Hopeless and untrustworthy Management. Get out !
mallorca 9
13/8/2021
09:06
market clearly expecting a lot more but this is overdone now IMV. The order book for the business (excluding any orders for the China partner and the acquired BBI business) is higher than at the same time last year, indicating good growth in the core business guess I should not be surprised that COVID has had a big impact - but the world will progress towards normality as they indicate in the outlook: The second half will have a more meaningful contribution from the new acquisitions and the business is well placed to benefit from the confidence that can be seen as the UK and global economies recover from the impact of Covid. The Board is excited by the growth opportunities available to the Group and looks forward to reporting further delivery on its strategy. Simon Thompson certainly has egg on his face this morning - wonder what he will say?!
melody9999
13/8/2021
08:51
So £8m was drawn on the RCF, will debt go up if profits not quite where they should be? Also that was done in late June, so we sit mid-Aug with that RNS? I should think there will be some mightily annoyed bankers / advisors IMO..... Debt if still at that level is manageable with c 1X EBITDA in future (think covenant may be trailing though), so just need to watch out in case they disappoint again IMO......DYOR and am off board for a while now after that nonsense.....thankfully my copper miners are marching ahead haha!
qs99
13/8/2021
08:50
The geo-politics re "everything China" are inescapable, whatever the detailed issues. I hope VLG drain whatever they can from the current deals - and possible future, whatever - but keep a guarded approach overall and look mainly to other aspects of the business for future successes.
hew
13/8/2021
08:42
FB, you may well be right.....not sure tbf it was as early as last year, but fair play if you spotted it early Many long standing VLGers like me, who have bagged or more, probably had too many blinkers on, but the deals looked great value IMO and seemed to have momentum again, but to be told the big China deal was not all it was cracked up to be, is pretty poor, as china has not been in lockdown which IMO points to something more fundamental an issue with the distributor.... DYOR
qs99
13/8/2021
08:33
FarnesBarnes25 Nov '20 - 21:15 - 725 of 1090 Edit 0 0 1 I'm not sure why, but something about VLG suddenly doesn't feel quite right to me. I can't put my finger on it. Within the last month, there's been a 20% fall in 4 days, followed by a near 50% rise the next 4 days, followed by this equity raise and director selling. I hope I'm wrong but something seems fishy. Suffering the same fate as BOTB, albeit, this is the first VLG profit warning. Two more to come.
farnesbarnes
13/8/2021
08:31
potential is there which is why I bought in, but management IMO have let the market down albeit market things are not necessarily in their control, more the communications etc. How long have they known that China was a dud vs the deal announcement IMO as someone pointed out above, we had a snippet much earlier in calendar year, but the sales have been appalling. No doubt they have been wanting to keep market "not" disappointed, how would they have done their deals after this sort of announcement for instance or raised the new debt facilities? Thinking about it more, I'm even more disappointed as was a very big fan of their ability to squeeze great things out of new/old products and run the business effectively. now they are on catch up IMO to gain credibility and that may take some time. Have sold a big chunk of my holding on the back of this, keeping a small amount for interest in case they can prove otherwise. DYOR
qs99
13/8/2021
08:24
back to the support at 80p now and a good buy at this level I would have thought. handsanitiser could have been expected but they need to sort out the Chinese partner but no maasive change to prospects here - just unexpected consumer buying patterns
melody9999
13/8/2021
08:10
Think the fall will be clawed back to some degree but management now have to up their game massively to retain confidence IMO! Let’s see whether they can convince market of potential and start delivering organic growth
qs99
13/8/2021
07:50
Cenkos have increased 2021 revenue forecasts by 8% to £35.9m, with a cash adjusted P/E of 20.4. The cash adjusted P/E now falls to 15.1 next year based on £46m revenues and £8.2m PBT, up from £4.4m PBT this year given the acquisitions. They retain their BUY, and summarise: "Venture Life has provided a trading update for the 6-months to June 2021 and its recent acquisitions. The company expects H1/21E revenues to be £13.8m versus £16.9m for H1/20A, the decline due to lower Chinese Dentyl and hand sanitiser gel (HSG) sales despite the rest of the business delivering 9% growth. We have updated our forecasts to reflect the current trading and recently announced acquisitions and have extended forecasts to include FY22E. Reflecting the trading update data and the two recent acquisitions, our FY21E revenue forecast has increased to c£36m from c£33m. While the issues with Dentyl in China and sales of HSG are disappointing, we believe Venture Life is in a solid position to grow revenues and profits and still retains meaningful firepower to complete additional acquisitions to further bolster growth. We maintain out Buy recommendation."
rivaldo
13/8/2021
07:43
Perhaps VLG could up its Board's reputation for ethical behaviour by recruiting David Cameron as a anon-Exec.
shanklin
13/8/2021
07:40
VLG is on c.4x sales. Two things rocked the share price hard in 2020: China contract and HS. The first indication the China contract was a dud was the February T/U: "There were no further shipments of product to our Chinese oral care partner in H2, but shipments are due to resume in H1 2021." They've been walking that contract down since and today totally fessed up to the market.
simon gordon
13/8/2021
07:35
Indeed Shanklin. The core business outside the two "one-off" areas of hand sanitiser and Dentyl China is up 9%, and the order book is higher - but those two areas are appalling. Funnily enough, VLG are on course to easily exceed Cenkos' current revenue target of £33.3m for this year given a full 6-month contribution from BBI plus the impact of the recent HCIP acquisition. But I assume Cenkos were planning to increase their forecast to account for the acquisitions' impact, and that increase may be cut back now.
rivaldo
Chat Pages: 1441  1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  Older
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211025 01:06:59